T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.55% |
| 2 | Healthcare | 16.29% |
| 3 | Consumer Discretionary | 15.56% |
| 4 | Financials | 12.85% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Warner Bros
WBD
$69.5B
| $11.1M | ﹤0.01% |
255,635
-19,112
| -7% | -$954K |
|
|
INFN
1377
DELISTED
Infinera Corporation Common Stock
INFN
| $11M | ﹤0.01% |
1,145,813
+1,036,214
| +945% | +$10.2M |
|
|
NGM
1378
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $11M | ﹤0.01% |
+379,463
| New | +$10.6M |
|
|
ELME
1379
Elme Communities
ELME
$144M
| $11M | ﹤0.01% |
498,853
-549,219
| -52% | -$12.5M |
|
|
MTEM
1380
DELISTED
Molecular Templates, Inc.
MTEM
| $10.7M | ﹤0.01% |
56,401
+54,375
| +2,684% | +$9.53M |
|
1381
Nektar Therapeutics
NKTR
$2.53B
| $10.6M | ﹤0.01% |
35,478
-1,115
| -3% | -$347K |
|
1382
Dell
DELL
$318B
| $10.6M | ﹤0.01% |
236,606
+43,256
| +22% | +$1.77M |
|
|
BHVN
1383
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $10.6M | ﹤0.01% |
154,547
-169
| -0.1% | -$13.7K |
|
|
DADA
1384
DELISTED
Dada Nexus
DADA
| $10.5M | ﹤0.01% |
386,741
-175,103
| -31% | -$6.66M |
|
1385
Invitation Homes
INVH
$18.1B
| $10.4M | ﹤0.01% |
325,445
+6,023
| +2% | +$181K |
|
1386
Leggett & Platt
LEG
$1.32B
| $10.4M | ﹤0.01% |
226,922
-9,198
| -4% | -$409K |
|
|
AUY
1387
DELISTED
Yamana Gold, Inc.
AUY
| $10.3M | ﹤0.01% |
2,381,562
+406,308
| +21% | +$1.94M |
|
1388
Hydrofarm Holdings
HYFM
$7.48M
| $10.3M | ﹤0.01% |
17,100
-18,090
| -51% | -$12.7M |
|
1389
Royal Gold
RGLD
$19.5B
| $10.2M | ﹤0.01% |
94,656
+16,596
| +21% | +$1.77M |
|
1390
Unum
UNM
$14.8B
| $10.2M | ﹤0.01% |
364,864
+2,896
| +0.8% | +$75.2K |
|
1391
Regenxbio
RGNX
$698M
| $10M | ﹤0.01% |
294,547
+5,711
| +2% | +$244K |
|
1392
Madrigal Pharmaceuticals
MDGL
$11.8B
| $10M | ﹤0.01% |
85,541
-85,668
| -50% | -$9.99M |
|
1393
Syndax Pharmaceuticals
SNDX
$1.72B
| $9.82M | ﹤0.01% |
439,017
+267,578
| +156% | +$6.05M |
|
|
ORTX
1394
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $9.8M | ﹤0.01% |
134,953
-131
| -0.1% | -$9.3K |
|
1395
EPR Properties
EPR
$4.72B
| $9.7M | ﹤0.01% |
208,115
+103,541
| +99% | +$4.37M |
|
1396
Disc Medicine
IRON
$3B
| $9.65M | ﹤0.01% |
+25,000
| New | +$11.2M |
|
1397
Fidelity National Financial
FNF
$13.3B
| $9.64M | ﹤0.01% |
246,499
-21,388
| -8% | -$812K |
|
|
RXDX
1398
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $9.59M | ﹤0.01% |
+525,000
| New | +$10.8M |
|
1399
Orchestra BioMed
OBIO
$259M
| $9.55M | ﹤0.01% |
850,000
| – | – |
|
|
GAP
1400
The Gap Inc
GAP
$7.42B
| $9.35M | ﹤0.01% |
313,973
-24,793
| -7% | -$616K |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.